Results 71 to 80 of about 1,315,640 (306)
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Translation of pharmaceutical 3D printing to clinical point-of-care and industrial manufacturing.
Drug Delivery and Translational ResearchThree-dimensional printing of medicines is moving from feasibility to practice across hospital point-of-care manufacture, community-pharmacy compounding and industrial production. Recent signals include a point-of-care printed oral solid dosage form that
C. Gioumouxouzis +3 more
semanticscholar +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Pharmaceutical market in the Republic of Croatia [PDF]
Medicinski Glasnik, 2008 Most European health systems are currently undergoing reforms.According to the World Health Organization, the aim of the healthsystem reforms are health gains, and one of the issues brought tothe foreground with respect to this is cost-containment ...
Jerko Glavaš, Maja Lamza – Maronić
doaj
Pharma innovation: how evolutionary economics is shaping the future of pharma R&D.
Drug Discovery TodayThis paper describes the theory of evolutionary economics in the context of pharmaceutical R&D. In this context, the R&D productivity crisis acts as a key selection mechanism, and R&D, technology and industry trends provide mechanisms of variation ...
Alexander Schuhmacher
semanticscholar +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Annual Review of Resource Economics, 2019 Mastitis is the most important production disease in dairy farming, leading to considerable inefficiency in production. In 1992, an important paper describing a simple but very useful economic framework for production diseases in animal farming was ...
H. Hogeveen, W. Steeneveld, C. Wolf
semanticscholar +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Medication reconciliation in a hospital environment: Avoided discrepancies and cost savings - A single arm intervention study: Benefits of medication reconciliation in a hospital [PDF]
Brazilian Journal of Pharmaceutical SciencesMedication reconciliation has proven to be essential for patient safety. However, studies on its economic viability are still scarce. Therefore, the aim of this study was to understand the avoided cost of medication discrepancies identified through the ...
Lays Cássia Santos Duarte +5 more
doaj +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source